Acta Dermato Venereologica,
Год журнала:
2023,
Номер
103, С. adv13363 - adv13363
Опубликована: Дек. 14, 2023
Atopic
dermatitis
is
a
common
inflammatory
disease
with
chronic
and
relapsing
course.
Although
considered
childhood
disease,
it
now
evident
that
atopic
also
in
adulthood
the
elderly
population.
typically
manifests
bilateral
symmetrical
eczematous
lesions
on
face,
trunk
skin
folds.
Itch
invariably
present
may
be
very
severe,
markedly
affecting
daily
life
sleep.
In
older
adults,
have
high
level
of
impact
quality
life,
frequently
burdening
an
already
complex
comorbid
situation.
The
full
assessment
burden
(localizations,
itch
severity,
sleep
alterations,
history,
comorbidities)
crucial
to
identify
most
appropriate
treatment.
many
cases,
moderate-to-severe
population
can
successfully
safely
treated
biological
agents
inhibiting
interleukin-4/-13
pathway,
whereas
use
Janus
kinase
inhibitors
pose
concerns
about
safety
profile.
Pharmaceutics,
Год журнала:
2023,
Номер
15(6), С. 1724 - 1724
Опубликована: Июнь 14, 2023
Atopic
dermatitis
(AD)
is
a
chronic
eczematous
inflammatory
disease
that
may
arise
from
environmental,
genetic,
and
immunological
factors.
Despite
the
efficacy
of
current
treatment
options
such
as
corticosteroids,
approaches
are
mainly
focused
on
symptom
relief
present
certain
undesirable
side
effects.
In
recent
years,
isolated
natural
compounds,
oils,
mixtures,
and/or
extracts
have
gained
scientific
attention
because
their
high
efficiency
moderate
to
low
toxicity.
promising
therapeutic
effects,
applicability
healthcare
solutions
somewhat
limited
by
instability,
poor
solubility,
bioavailability.
Therefore,
novel
nanoformulation-based
systems
been
designed
overcome
these
limitations,
thus
enhancing
potential,
promoting
capacity
drugs
properly
exert
action
in
AD-like
skin
lesions.
To
best
our
knowledge,
this
first
literature
review
has
summarizing
loaded
with
ingredients,
specifically
for
management
AD.
We
suggest
future
studies
should
focus
robust
clinical
trials
confirm
safety
effectiveness
natural-based
nanosystems,
paving
way
more
reliable
AD
treatments.
Frontiers in Medicine,
Год журнала:
2023,
Номер
10
Опубликована: Авг. 16, 2023
Atopic
dermatitis
(AD)
is
a
chronic
inflammatory
disease
with
heterogeneous
pathogenesis
correlated
dysregulation
of
the
immune
system
and
prevalence
T2-mediated
pathway.
Recent
understanding
AD
has
allowed
development
new
drugs
targeting
different
mechanisms
cytokines
that
have
changed
treatment
approach.
The
aim
this
review
to
update
knowledge
on
standard
care
recent
advancements
in
control
skin
inflammation.
In
light
guidelines,
we
report
clinical
efficacy
novel
treatments,
special
attention
situations
where
biologics
small
molecules
are
involved.
Acta Dermato Venereologica,
Год журнала:
2023,
Номер
103, С. adv13363 - adv13363
Опубликована: Дек. 14, 2023
Atopic
dermatitis
is
a
common
inflammatory
disease
with
chronic
and
relapsing
course.
Although
considered
childhood
disease,
it
now
evident
that
atopic
also
in
adulthood
the
elderly
population.
typically
manifests
bilateral
symmetrical
eczematous
lesions
on
face,
trunk
skin
folds.
Itch
invariably
present
may
be
very
severe,
markedly
affecting
daily
life
sleep.
In
older
adults,
have
high
level
of
impact
quality
life,
frequently
burdening
an
already
complex
comorbid
situation.
The
full
assessment
burden
(localizations,
itch
severity,
sleep
alterations,
history,
comorbidities)
crucial
to
identify
most
appropriate
treatment.
many
cases,
moderate-to-severe
population
can
successfully
safely
treated
biological
agents
inhibiting
interleukin-4/-13
pathway,
whereas
use
Janus
kinase
inhibitors
pose
concerns
about
safety
profile.
